Inquiry Basket
Loading ......
Few public-health interventions have reshaped a bacterial disease as dramatically as conjugate vaccines reshaped pneumococcal disease. Within a decade of routine childhood immunisation, invasive pneumococcal disease caused by vaccine serotypes collapsed in country after country, and herd protection extended benefits to unvaccinated adults. Yet the pneumococcus is an adaptable organism. Today the central epidemiological story is no longer simply "vaccines work"—it is how the bacterium fills the ecological space vaccines create, and how unevenly that protection reaches the world's children. Understanding the post-vaccine era means following serotype replacement, nasopharyngeal carriage and the surveillance tools that expose where detection still falls short.
The seven-valent conjugate vaccine, introduced in the early 2000s, was followed by ten-valent and thirteen-valent formulations that together targeted the serotypes responsible for most childhood disease. The effect was swift and large. In South Africa, where the seven-valent vaccine was introduced in the late 2000s and the thirteen-valent shortly afterwards, fifteen years of national laboratory-based surveillance showed that invasive pneumococcal disease in children younger than two years fell by 76% over that period, with vaccine-serotype disease declining by more than 93%. Belgium, which unusually switched sequentially between conjugate formulations, documented a low point in paediatric invasive disease during the thirteen-valent period before a partial rebound after a switch to the ten-valent product—evidence that the precise serotype mix in a vaccine matters for population outcomes. Indirect effects were striking too: as vaccinated children stopped carrying vaccine serotypes, unvaccinated older siblings, parents and grandparents gained protection. The success is real, but it is also the prologue to a new problem.
Because more than ninety capsular serotypes exist, removing the dominant vaccine types leaves ecological room for others. This "serotype replacement" is not random. Whole-genome sequencing of childhood invasive disease across six countries showed that replacement is often mediated by expansion of non-vaccine serotypes within lineages that previously carried vaccine serotypes, and by the spread of globally successful lineages such as GPSC3 expressing serotype 8 in some settings and serotype 33F in others. Crucially, the same non-vaccine serotype can display very different antibiotic-resistance profiles in different places, because local selective pressures differ. A meta-analysis of invasive disease potential found that serotypes such as 1, 7F and 12F carry high inherent invasiveness in young children, while several non-vaccine serotypes sit at the upper end of the invasiveness spectrum and are precisely those now emerging. Higher-valency conjugate vaccines covering fifteen and twenty serotypes were developed to capture this residual burden, and early post-licensure dynamics show they do prevent a meaningful share of the disease that remained after the thirteen-valent vaccine—yet replacement pressure simply shifts again toward the serotypes still excluded.
Figure 1. Effects of pneumococcal vaccination on pneumococcal carriage, and mechanisms that cause serotype replacement. (Source: Steens Anneke, et al. 2019)
Children under five remain the age group with the highest incidence of invasive pneumococcal disease, and conjunctivitis, otitis media and pneumonia in this group are still driven substantially by vaccine and closely related serotypes. But the post-vaccine era has exposed a growing elderly burden. In South Africa, adults older than 64 years enjoyed an overall decline in invasive disease, yet non-vaccine serotypes increased by more than 200% in that group, reflecting both intrinsic ageing of immunity and the fact that older adults were never directly vaccinated in many programmes. In settings where older adults now receive conjugate vaccines, disease attributable to the added serotypes falls—but the remaining non-vaccine serotypes continue to circulate in the community, sustained by childhood carriage. The epidemiological centre of gravity has therefore moved: paediatric disease is better controlled than ever, while adult and especially geriatric invasive pneumococcal disease is increasingly a disease of serotypes the original vaccines never covered. This shift reframes "pneumonia vaccine adults" from an optional query into a core prevention question.
Carriage is the keystone of pneumococcal biology. The bacterium colonises the nasopharynx of healthy children at rates of 20–85% depending on age and setting, and carriage is the reservoir from which both transmission and disease spring. Importantly, carriage and disease are not the same: a serotype common in the nose may be a weak invader, while a rarer serotype may be highly invasive. This is why carriage surveys have become essential surveillance tools, particularly where sterile-site cultures are hard to obtain. Molecular studies using quantitative PCR on nasopharyngeal swabs from healthy Canadian children found pneumococcal DNA in roughly half of samples—far more than culture alone detected—and showed that vaccine serotypes persist in carriage even after universal childhood vaccination. In Vietnam, a systematic review of carriage in children estimated a pooled prevalence of 33%, with vaccine serotypes such as 6A, 19F, 6B and 23F dominating colonisation and with strikingly high rates of non-susceptibility to penicillin and macrolides among carried isolates. Carriage is thus both a transmission engine and an early-warning system for resistance.
Figure 2. Molecular mechanisms of pneumococcal colonization of host surfaces. (Source: Weiser JN, et al. 2018)
Because invasive disease is rare relative to carriage, carriage surveys double as the most practical meter of vaccine impact in resource-limited settings. A fall in vaccine-type carriage after introduction signals that the vaccine is working at the population level even when sterile-site surveillance is weak, while a rise in non-vaccine-type carriage warns of replacement years before it shows up in meningitis or sepsis statistics. Molecular serotyping of carriage swabs—using the same capsular-locus PCR and sequencing approaches applied to invasive isolates—lets programmes track both trends with modest infrastructure. The Vietnam review illustrates the payoff: a 33% carriage prevalence dominated by vaccine types argues strongly for introduction, while high carriage resistance argues that vaccine prevention, not just antibiotic treatment, is the sustainable lever. Detection and prevention thus close the loop.
Tracking this moving ecology demands practical detection. Reference serotyping still depends on research-grade anti-pneumococcal antibodies and pneumococcal capsular polysaccharide antigens, used in the Quellung reaction and in latex agglutination, with molecular multiplex PCR and whole-genome sequencing increasingly inferring serotype from the capsular locus. For field and outbreak settings, lateral-flow immunochromatographic formats that capture capsular or C-polysaccharide antigen offer a route to rapid, low-infrastructure testing—useful not as a replacement for culture but as a triage and surveillance layer where laboratories are scarce. The research utility here is broad: well-characterised recombinant pneumococcal antigens and validated antibodies let surveillance networks standardise serotype calls, monitor replacement in near real time, and quantify carriage prevalence without shipping every swab to a central facility. Detection gaps are largest exactly where they matter most—in low-resource regions with high disease burden and limited sterile-site sampling—so cheap, robust antigen and molecular tools are not a convenience but a prerequisite for equitable surveillance.
The post-vaccine dividend has been distributed profoundly unevenly. Global modelling estimates that thirteen-valent conjugate vaccination could prevent roughly 400,000 child deaths each year, yet the countries eligible for Gavi support account for the large majority of those preventable deaths while bearing only a fraction of the cost. Many high-burden countries introduced conjugate vaccines late or not at all, and the COVID-19 pandemic interrupted routine immunisation, eroding coverage gains. Vietnam, for example, had not yet introduced conjugate vaccine into its national programme as its carriage studies were conducted, despite a high prevalence of vaccine-type colonisation and substantial antibiotic resistance—a textbook case of a preventable disease persisting for want of access. Even where vaccines are introduced, the choice between formulations with different serotype coverage changes which non-vaccine serotypes will later emerge, making local surveillance indispensable. Closing detection gaps and closing access gaps are two sides of the same effort: without knowing what circulates, countries cannot choose vaccines wisely, and without vaccines, the most effective surveillance finding—that a preventable death is occurring—goes unacted.
References
| Target | Cat. No. | Product Name | Species | Application | Detection Sample | |
| S. pneumoniae | DEIA23G | Human Anti-S. Pneumococcal vaccine (Pneumovax/CPS23) IgG ELISA Kit | Human | Quantitative | Serum, Plasma | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| S. pneumoniae | DAG-WT3613 | Inactivated Streptococcus pneumoniae Culture Fluid (strain 262) | N/A | N/A | Control | Inquiry |
| DAG-WT559 | S. pneumoniae Type 6A Capsule Polysaccharide (CPS) | S. pneumoniae | N/A | ELISA, CLIA, LFIA | Inquiry | |
| DAG-WT560 | Inactivated S. pneumoniae Type 64Z Antigen | N/A | Unconjugated | Immunogen, WB, ELISA | Inquiry | |
| DAGC700 | S. pneumoniae Type 1 Capsule Polysaccharide (CPS) | S. pneumoniae | N/A | ELISA, CLIA, LFIA | Inquiry | |
| DAGC701 | S. pneumoniae Type 2 Capsule Polysaccharide (CPS) | S. pneumoniae | N/A | ELISA, CLIA, LFIA | Inquiry | |
| DAG-WT7444 | Inactivated S. pneumoniae Type 23F Culture Fluid | S. pneumoniae | N/A | Control | Inquiry | |
| DAG-WT7129 | Inactivated Natural Streptococcus pneumoniae Quality Control | N/A | N/A | Immunoassays | Inquiry | |
| S. pneumoniae CWPS | DAG2685 | S. pneumoniae Cell Wall Polysaccharide Antigen | N/A | Unconjugated | ELISA | Inquiry |
| DAG2686 | S. pneumoniae Cell Wall Polysaccharide Antigen | N/A | Unconjugated | ELISA | Inquiry |
Loading ......
